Until now, skeletal myoblasts and bone marrow cells were clinically used for donors, and the efficacy was shown in a certain... Read More >
Cell Transplantation Therapy For End-Stage Heart Failure-Enhanced Efficacy Of Transplantation By Control-Release Of Cell Growth Factor
Author; TAMBARA KEIICHI(Kyoto Univ., JPN) KOMEDA MASASHI(Kyoto Univ., JPN)
Abstract: We discuss cell transplantation for end-stage heart failure focusing to enhanced efficacy of the therapy by control-release of cell growth factor. To maintain enough blood concentrations of growth factors for a period of time, our colleagues developed biodegaradable gelatin hydrogel for control-release of growth factors. We applied the system to basic fibroblast growth factor (bFGF), and it was successfully applied to 2 patients with ungraftable ischemic areas by utilizing the omentum as a blood source. We demonstrated that bFGF-impregnated hydrogel enhanced the efficacy of skeletal myoblast transplantation (SMTx) to rat chronic myocardial infarction (MI) hearts by increasing graft volume (3-fold) and tissue blood flow. Also, we showed that hepatocyte growth factor greatly increased graft volume (7-fold) and vascularity and reduced fibrosis inside the graft, which enhanced the efficacy of SMTx to rat MI hearts. Because the effectiveness of SMTx is correlated to the graft volume, the graft-expansion strategy is reasonable. Until now, skeletal myoblasts and bone marrow cells were clinically used for donors, and the efficacy was shown in a certain, but not large, extent. It may be a promising strategy to use cell therapy in combination with surgery rather than as a sole remedy. (author abst.)
Journal Title; Tokyo Heart Journal
Journal Code: Z0890B
ISSN: 0285-6581
VOL.26; NO.2; PAGE.42-48(2006)
Figure&Table&Reference; FIG.2, REF.8
Pub. Country; Japan
Language; Japanese